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Contemporary point of care cardiac 
troponin testing in suspected acute 
coronary syndrome
Andrew R Chapman,  1 Stacey Stewart,1 Nicholas L Mills  1,2
Around one million patients present to 
hospital with chest pain every year, 
accounting for approximately 5% of all 
emergency department attendances in the 
UK. However, only one in five patients are 
found to have had a myocardial infarc-
tion.1 Therefore, for several years, there 
has been a drive to develop diagnostic 
strategies which allow accurate identifica-
tion of patients without myocardial infarc-
tion at an earlier stage, who may not 
require admission to hospital for serial 
cardiac biomarker testing. Such strategies 
have the potential to improve patient 
experience and optimise resource alloca-
tion both in the emergency department 
and in hospital, at a time of ever-increasing 
demands.
Cardiac troponin is the biomarker of 
choice for the detection of myocardial 
injury, and international guidelines recom-
mend concentrations are measured using 
a high-sensitivity assay.2 While high-sen-
sitivity assays were first introduced in 
Europe in 2010, they have only recently 
become available for use in clinical prac-
tice in the USA. The higher precision and 
lower limits of detection afforded by these 
tests has facilitated the development of 
pathways which can rule out myocardial 
infarction at an earlier stage, the majority 
of which have demonstrated a magni-
tude of benefits in diagnostic accuracy 
compared with using the recommended 
diagnostic threshold (99th centile) 
alone.3 4 In practical terms, implementa-
tion of these approaches requires invest-
ment in infrastructure to deliver accurate 
and timely cardiac troponin results on a 
high-sensitivity platform which is not 
always available.
One potential strategy to improve 
efficiency is through the use of point of 
care devices. Similar to blood glucose 
testing, the delivery of rapid and accu-
rate measurements of cardiac troponin 
at the bedside could allow earlier diag-
nosis or rule out of myocardial infarc-
tion in practice see figure 1. Body et al 
report results from a prospective cohort 
study evaluating the diagnostic accuracy 
of the Troponin-only Manchester Acute 
Coronary Syndrome (T-MACS) decision 
aid when applied using a contemporary 
point of care cardiac troponin I assay. 
The Abbott iSTAT point of care assay has 
a reported 99th centile of 80 ng/L and 
limit of detection of 20 ng/L, with a coef-
ficient of variation of 16.5% at the 99th 
centile diagnostic threshold.5 In this study, 
cardiac troponin I concentrations were 
measured on a central laboratory plat-
form and on the point of care device in 
716 patients across eight sites in England. 
When T-MACS was applied with the 99th 
centile of the iSTAT assay at 0 and 3 hours, 
the authors report excellent diagnostic 
accuracy, with an Negative predictive 
value (NPV) of 99.5% (95% CI 96.5% to 
99.9%) and sensitivity of 99.0% (95% CI 
94.4% to 100%), for a primary outcome 
of myocardial infarction, coronary revas-
cularisation or all-cause death at 30 days.
While the findings of Body et al are 
encouraging, there are important limita-
tions to consider. First, the majority of 
patients were male (74.3%), and only those 
with symptoms for less than 12 hours were 
included. Although this may reduce the 
generalisability of the findings, focusing 
on patients with a shorter duration of 
symptoms would be expected to reduce 
diagnostic accuracy, as troponin release 
is a time-dependent phenomenon. Blood 
samples were obtained at the bedside but 
were processed by research nurses not 
involved in patient care, so the impact 
on diagnostic efficiency is unmeasurable. 
Finally, in keeping with the majority of 
studies in this area, the results are based 
on observational data. Patients were not 
managed on the basis of test results and 
may have undergone additional investiga-
tions and management which could have 
influenced their outcomes. Importantly, 
local validation of this approach is essen-
tial to adjust for differences in population 
level characteristics and the pretest proba-
bility of disease which may influence diag-
nostic performance.
It should be acknowledged that it is 
difficult to conduct observational cohort 
studies in patients with suspected acute 
coronary syndrome that replicate real 
world clinical practice. Indeed, in the 
majority of studies evaluating cardiac 
troponin use, the symptom onset to 
sample time is around 6 hours. With the 
availability of bedside testing, this time 
may significantly fall and diagnostic 
performance may be less robust. Further-
more, the availability of easily accessible 
bedside troponin testing may lead to less 
selective, non-judicious testing which 
could lead to an increase in the diagnosis 
of type 2 myocardial infarction or myocar-
dial injury.6
Although the focus of the study of 
Body et al is on the in-hospital use 
of point of care testing, there are a 
number of novel approaches which 
could be transformative for clinical 
practice. Prehospital use may facilitate 
the evaluation of suspected myocardial 
infarction in the community, allowing 
redirection of patients with a higher 
probability of myocardial infarction to 
cardiac centres, and low risk patients 
to district general hospitals. The 
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Figure 1 Point of care compared with central laboratory testing for cardiac troponin in patients 
with suspected acute coronary syndrome.
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Pre-hospital Evaluation of Sensitive 
Troponin study will evaluate the perfor-
mance of pre-hospital cardiac troponin 
testing (NCT:03561051). The study 
aims to recruit 700 patients who have 
phoned the emergency services with 
symptoms suspicious for acute coronary 
syndrome before they arrive at hospital. 
Blood samples will be obtained in the 
ambulance and on arrival to hospital. 
While tests will not be run live, this 
study will obtain samples as near to 
symptom onset as practicable, giving 
important insight into the diagnostic 
accuracy of point of care testing and 
allowing for validation of the T-MACS 
clinical risk score in this population.
In future, the diagnostic performance 
of point of care cardiac troponin assays 
is likely to improve. Recently, a novel 
point of care cardiac troponin I assay 
was described by Pickering et al in a pilot 
study of 354 patients. While not formally 
designated as a high-sensitivity assay, the 
Abbott TnI-Nx is capable of reporting 
concentrations from 1 to 1500 ng/L.7 In 
their evaluation, they found this assay 
could rule out myocardial infarction on 
the basis of a single troponin result, with 
comparable NPV and sensitivity to the 
established ARCHITECTSTAT high-sensi-
tivity cardiac troponin I laboratory plat-
form. Whether the addition of this novel 
assay to the T-MACS strategy could allow 
more patients to be identified as low risk 
in the emergency department remains 
unclear, but would be an important evalu-
ation in future.
Contemporary point of care cardiac 
troponin testing in combination with 
a clinical risk score may facilitate the 
rule-out of myocardial infarction in insti-
tutions without access to a high-sensitivity 
cardiac troponin platform. While novel, 
more sensitive point of care assays are in 
development, the encouraging findings of 
Body et al should lead to prospective vali-
dation studies to demonstrate the safety 
and efficacy of this approach.
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